Digoxin Quiz

Pharmacokinetics of Digoxin

• Digoxin clearance varies between 0.5 and 0.9 in tablet form and 0.8 in elixir form.
• Total digoxin clearance (Clt) is the sum of metabolic (Clm) and renal (Clr) clearances.
• Metabolic clearance of digoxin ranges from 0.57 to 0.86 mL/kg/min.
• Bioavailability in healthy individuals via intravenous route is 100%, but it decreases by 25% with St. John’s wort.
• Antibiotics, particularly macrolides, can alter digoxin concentrations and clearance.
• The half-life of digoxin ranges from 7 to 14 days, and it takes 15 to 20 days to achieve steady state.
• Digoxin is extensively distributed in tissues, with 70-80% free in blood plasma.
• Volume of distribution is affected by factors such as renal function, hypothyroidism, and drug interactions.
• Routine plasma samples for digoxin monitoring should be obtained just before the next dose.
• Pharmacokinetics of digoxin is altered in patients with end-stage renal disease and hypothyroidism.
• The distribution of digoxin follows a two-compartment model, with initial high serum concentrations not reflective of therapeutic or toxic potential.
• Plasma digoxin levels may not accurately reflect the drug’s pharmacological effect until after equilibration is complete.

Pharmacokinetics of Digoxin

• Digoxin clearance varies between 0.5 and 0.9 in tablet form and 0.8 in elixir form.
• Total digoxin clearance (Clt) is the sum of metabolic (Clm) and renal (Clr) clearances.
• Metabolic clearance of digoxin ranges from 0.57 to 0.86 mL/kg/min.
• Bioavailability in healthy individuals via intravenous route is 100%, but it decreases by 25% with St. John’s wort.
• Antibiotics, particularly macrolides, can alter digoxin concentrations and clearance.
• The half-life of digoxin ranges from 7 to 14 days, and it takes 15 to 20 days to achieve steady state.
• Digoxin is extensively distributed in tissues, with 70-80% free in blood plasma.
• Volume of distribution is affected by factors such as renal function, hypothyroidism, and drug interactions.
• Routine plasma samples for digoxin monitoring should be obtained just before the next dose.
• Pharmacokinetics of digoxin is altered in patients with end-stage renal disease and hypothyroidism.
• The distribution of digoxin follows a two-compartment model, with initial high serum concentrations not reflective of therapeutic or toxic potential.
• Plasma digoxin levels may not accurately reflect the drug’s pharmacological effect until after equilibration is complete.

Test your knowledge on the ionotropic agent primarily used to treat atrial fibrillation in patients with congestive heart failure (CHF). Explore dosage, administration, and considerations for patients with renal impairment.